Sanara Medtech Inc
Health Care
Sanara Medtech Inc (SMTI) Stock News
The latest SMTI headlines and market coverage — 4 recent stories, updated throughout the day.
- GlobeNewswire Inc.·
Halper Sadeh LLC is Investigating Whether FBRX, LXFR, SMTI, MKTX are Obtaining Fair Deals for their Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating four companies for potential violations of federal securities laws and breaches of fiduciary duties related to their proposed acquisitions. The firm is examining whether insiders are receiving substantial benefits unavailable to ordinary shareholders and whether transaction terms limit competing offers. The investigations cover Forte Biosciences' sale to argenx, Luxfer Holdings' sale to Wynnchurch Capital affiliates, Sanara MedTech's sale to MiMedx Group, and MarketAxess Holdings' sale to Intercontinental Exchange.
- GlobeNewswire Inc.·
Halper Sadeh LLC is Investigating Whether MKTX, SMTI, LNTH are Obtaining Fair Deals for their Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating three companies for potential securities law violations and breaches of fiduciary duties related to their proposed acquisitions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be limiting superior competing offers.
- GlobeNewswire Inc.·
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: MarketAxess Holdings Inc. (Nasdaq – MKTX), CBIZ, Inc. (NYSE – CBZ), Sanara MedTech Inc. (Nasdaq – SMTI), TriCo Bancshares (Nasdaq – TCBK)
Law firm Brodsky & Smith announced investigations into four major merger transactions, examining whether the boards of MarketAxess Holdings, CBIZ, Sanara MedTech, and TriCo Bancshares breached fiduciary duties by failing to conduct fair processes and potentially underpaying shareholders. The firm is seeking shareholders to discuss potential class action lawsuits.
- The Motley Fool·
Sanara MedTech (SMTI) Q1 2026 Earnings Transcript
Sanara MedTech reported strong Q1 2026 results with 19% year-over-year revenue growth to $27.8 million, driven by increased sales of soft tissue repair products CellerateRX and BIASURGE. The company achieved GAAP net profitability with $0.4 million net income ($0.04 per diluted share), improved gross margins to 93%, and paid debt service entirely in cash for the first time. Management maintained full-year 2026 guidance of $116-121 million revenue (13-17% growth) and expects OsStic synthetic bioadhesive product launch in Q1 2027.